Tianwang Buxin Pill improves cognitive function in APP/PS1 mice by reducing neuronal damage and regulating synaptic...

Area of Science:

• Neuroscience
• Pharmacology
• Traditional Chinese Medicine

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
• Tianwang Buxin Pills (TWBXP), a traditional Chinese medicine, shows potential for treating AD-related cognitive decline.
• The precise mechanisms underlying TWBXP's effects in AD require further elucidation.

Purpose of the Study:

• To systematically evaluate TWBXP's impact on cognition, neuronal damage, and synaptic plasticity in AD mouse models.
• To clarify the underlying therapeutic mechanisms of TWBXP in Alzheimer's disease.

Main Methods:

• Quality control of TWBXP using HPLC-UV.
• Administration of TWBXP to APP/PS1 mice for 8 weeks, followed by behavioral tests.
• Assessment of AD pathology via Immunohistochemistry, Western blotting, ELISA, TEM, and Immunofluorescence.
• Integration of Network Pharmacology and Proteomics to explore mechanisms.

Main Results:

• TWBXP significantly improved cognitive performance and reduced amyloid-beta (Aβ) burden in mice.
• TWBXP promoted M2 microglial polarization, reduced neuroinflammation, and enhanced Aβ clearance.
• Neuroprotective and synaptic protective effects were observed, including increased neuronal and synaptic protein levels and improved synaptic plasticity.

Conclusions:

• TWBXP ameliorates cognitive impairment and AD pathology in APP/PS1 mice.
• Therapeutic effects are linked to the regulation of microglial function and the cAMP/PKA/NR2B/CaMKII signaling axis.
• TWBXP demonstrates potential as a therapeutic agent for Alzheimer's disease.